• Treffer 8 von 13
Zurück zur Trefferliste

Endothelin and Tubulointerstitial Renal Disease

  • All components of the endothelin (ET) system are present in renal tubular cells. In this review, we summarize current knowledge about ET and the most common tubular diseases: acute kidney injury (AKI) and polycystic kidney disease. AKI originally was called acute tubular necrosis, pointing to the most prominent morphologic findings. Similarly, cysts in polycystic kidney disease, and especially in autosomal-dominant polycystic kidney disease, are of tubular origin. Preclinical studies have indicated that the ET system and particularly ETA receptors are involved in the pathogenesis of ischemia-reperfusion injury, although these findings have not been translated to clinical studies. The ET system also has been implicated in radiocontrast-dye-induced AKI, however, ET-receptor blockade in a large human study was not successful. The ET system is activated in sepsis models of AKI; the effectiveness of ET blocking agents in preclinical studies is variable depending on the model and the ET-receptor antagonist used. Numerous studies have shownAll components of the endothelin (ET) system are present in renal tubular cells. In this review, we summarize current knowledge about ET and the most common tubular diseases: acute kidney injury (AKI) and polycystic kidney disease. AKI originally was called acute tubular necrosis, pointing to the most prominent morphologic findings. Similarly, cysts in polycystic kidney disease, and especially in autosomal-dominant polycystic kidney disease, are of tubular origin. Preclinical studies have indicated that the ET system and particularly ETA receptors are involved in the pathogenesis of ischemia-reperfusion injury, although these findings have not been translated to clinical studies. The ET system also has been implicated in radiocontrast-dye-induced AKI, however, ET-receptor blockade in a large human study was not successful. The ET system is activated in sepsis models of AKI; the effectiveness of ET blocking agents in preclinical studies is variable depending on the model and the ET-receptor antagonist used. Numerous studies have shown that the ET system plays an important role in the complex pathophysiology associated with cyst formation and disease progression in polycystic kidney disease. However, results from selective targeting of ET-receptor subtypes in animal models of polycystic kidney disease have proved disappointing and do not support clinical trials. These studies have shown that a critical balance between ETA and ETB receptor action is necessary to maintain structure and function in the cystic kidney. In summary, ETs have been implicated in the pathogenesis of several renal tubulointerstitial diseases, however, experimental animal findings have not yet led to use of ET blockers in human beings. (C) 2015 Elsevier Inc. All rights reserved.zeige mehrzeige weniger

Metadaten exportieren

Weitere Dienste

Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Verfasserangaben:Albert C. M. Ong, Karoline von WebskyORCiDGND, Berthold HocherORCiDGND
DOI:https://doi.org/10.1016/j.semnephrol.2015.03.004
ISSN:0270-9295
ISSN:1558-4488
Pubmed ID:https://pubmed.ncbi.nlm.nih.gov/25966351
Titel des übergeordneten Werks (Englisch):Seminars in nephrology
Verlag:Elsevier
Verlagsort:Philadelphia
Publikationstyp:Rezension
Sprache:Englisch
Jahr der Erstveröffentlichung:2015
Erscheinungsjahr:2015
Datum der Freischaltung:27.03.2017
Freies Schlagwort / Tag:ADPKD; ET-1; ETA; ETB; Endothelin; acute kidney injury; polycystic kidney disease
Band:35
Ausgabe:2
Seitenanzahl:11
Erste Seite:197
Letzte Seite:207
Organisationseinheiten:Mathematisch-Naturwissenschaftliche Fakultät / Institut für Ernährungswissenschaft
Peer Review:Referiert
Verstanden ✔
Diese Webseite verwendet technisch erforderliche Session-Cookies. Durch die weitere Nutzung der Webseite stimmen Sie diesem zu. Unsere Datenschutzerklärung finden Sie hier.